Trustee & Chair - Amanda Cordell 

Amanda is the founder of EOS Network. A patient advocate of 14 years initiating the first UK Eosinophilic Yahoo support group in 2005.  Completing the Eurordis Patient expert training in advocacy for rare disease research in 2018 has supported her ongoing role as the patient's voice within multiple national (BSG - BSPGHAN) and international (EUREOS - CEGIR) working groups and consortiums. Amanda has a career industry background in finance and business management.

At the heart of her inspiration are her two children with Eosinophilic disease, their difficulties in being able to participate in the basic function of eating and breathing without pain has been her motivation to strive for further understanding, support and treatment for the past 17 years.  

Amanda is confident that by creating this hub for patients, global knowledge and interest in Eosinophilic Associated Diseases, EOS Network and is members will together improve diagnosis, ongoing care and treatment for all affected.




Trustee - David Cordell

David is a patient advocate of 14 years and father of two eosinophilic children. After spending the last 17 years reading any literature publicly available in order to better understand his children’s conditions, David is delighted to be able to be a part of EOS Network, ensuring families can be supported by receiving credible information. With a life long career in Engineering David considers everything is repairable if you know how and as such he supports the charities objectives in raising funds for research into finding treatments and a CURE for Eosinophilic Diseases.   



Trustee - David Evans 

David has had an extensive career in finance and operations within the global medical device industry, living and working in Europe, USA and South East Asia.

David also has past charity trustee experienced whilst volunteering for the Citizens Advice Bureau. He plays an important active role ensuring we adhere to policies and charity compliance as Secretary and Treasurer for EOS Network.

 

 




Medical Advisor - Professor Stephen Attwood

Stephen is a surgeon in the UK who identified Eosinophilic Oesophagitis (EoE) in 1987 (first abstract published 1989). He has since been involved in the care of patients with EoE for 30 years, and is author of a number of papers and guidelines on the condition.

Stephen is an Honorary Professor in  Health Services Research at Durham University, and a retired Consultant Gastro-Intestinal Surgeon,  specialising in Upper GI and Minimally Invasive Surgery at Northumbria Healthcare Trust.

He has been Chairman of the Oesophageal Section of British Society of Gastroenterology, a member of the Guts-UK (previously Core) Research Awards Committee and an advisor to NICE on Interventional Devices in  Gastroenterology.

Currently, Stephen is the UK Chief Investigator for a Phase 3 clinical trial on drug therapy for Eosinophilic Oesophagitis. He has a wide range of other research interests in diseases of the oesophagus. He chairs the Data Monitoring Committee of two national trials:  BEST3, a study of the screening for Barrett’s Oesophagus in GP practices and Endobarrier, a UK study of endoscopic antiobesity therapy. Stephen has been part of the design and trial management of the ASPECT trial of cancer prevention in Barrett’s Oesophagus,  and The LOTUS Trial. (Anti-Reflux Surgery vs PPI).  His research in gastroesophageal reflux also includes studies of a neuromodulator of the lower oesophageal sphincter. 



Medical Advisor - Dr Sarmed Sami MBChB, MRCP, PGCME, PhD Associate Professor of Gastroenterology, University College London Consultant Gastroenterologist, NHS Trust

Dr Sami had the privilege of training and practising medicine in three different continents!  After qualifying from Baghdad Medical School in 2003, he moved to the UK where he trained in Medicine and Gastroenterology at several hospitals. He completed a 3-year prestigious National Endoscopy Research Fellowship at the NIHR Nottingham Biomedical Research Centre leading to the award of a PhD. Following which, Dr Sami undertook a 1-year advanced oesophageal fellowship at the Mayo Clinic, Rochester, USA. He was part of a team looking after one of the largest cohorts of patients with eosinophilic oesophagitis (EoE) in the world. As a result, he developed extensive knowledge and expertise in all aspects of care for those patients.

Dr Sami is proud to be the recipient of several awards including the Cook Medical Marsha Dreyer award from the American Society for GI Endoscopy (ASGE); the British Society of Gastroenterology (BSG) out of programme award; and more recently, the Fellows-in-training award from the American College of Gastroenterology (ACG). He is also the lead author and co-author of over 40 high impact peer-reviewed publications and research abstracts in the field of Gastroenterology including the current UK guidelines on oesophageal dilatation.


Medical Advisor - Dr Marcus KH Auth MD PD FRCPCH Consultant Paediatric Gastroenterologist, Alder Hey Children's Hospital, Honorary Lecturer University of Liverpool, BSPGHAN EoE Working Group Chair

Dr Auth is a renowned national and European and global expert, actively involved in several clinical and scientific working groups on EGID, IBD, polyposis syndromes, endoscopy, GI physiology and coeliac disease.

Currently, he is a consultant in Paediatric Gastroenterology at Alder Hey Children’s NHS, Lead consultant and founder of the Northwest Network for Paediatric Gastroenterology, Hepatology and Nutrition - Foundation Trust, senior fellow of the Royal College of Paediatric Children Health (RCPCH) and a senior member of the British and European Societies of Paediatric Gastroenterology (BSPGHAN and ESPGHAN).

Dr Auth has published more than 80 publications in peer-reviewed journals and given several hundred presentations, including national audits and international guidelines.



Scientific Research and Drug Development Advisor - Mr Duncan Judd - CEO of Awridian Ltd.  


Duncan is an experienced Medicinal Chemist in lead generation and optimisation, with a 39-year proven track record at a blue-chip Pharma. Duncan has a unique comprehension of target and compound tractability and is at the forefront of innovation in drug discovery: establishing foundations for high throughput chemistry and pivotal in compound acquisition for lead generation.  He has published widely and has a strong network in the industry and established Awridian Ltd, a consultancy company, that is working with both industry and academia making a difference.

 

 


Patient advocate for Adult EOE - Carol Read RN/MSc

Carol is a nurse innovator who has had extensive experience as a clinician within the NHS at Local and NHS England level, including digital health, innovation, education, intensive care, radiology and endoscopy.  She has been diagnosed with EOE since 2017, after a history of the disease for over twenty years.  Passionate about improving the management and diagnosis of the disease through the dual experience of clinician/patient. Carol has raised the profile of EOE and its impact on patients at International conferences such as Stanford University MedX 2018, through webinars with primary care networks and feedback on patient experience to NICE.






Help us continue our work within EOS Network

Please select a donation amount: *
Set up a regular payment Donate

Registered Charity 1143267

Last updated 23/01/20 ©EOS Network 2020 All rights reserved